Sonnet BioTherapeutics Holdings (SONN): Rasio rega marang prakiraan pendapatan
Management of Sonnet BioTherapeutics (SONN) involves binary risks and a dependence on investment. The laboratory develops targeted immunomodulators to combat terminal metastases, however, the R&D stage and lack of sales keep costs elevated. The issuer's forward P/S visualizes market expectations for future sales, while the value 8.90 denotes the current figure for this metric.
Rincian analitis perusahaan Sonnet BioTherapeutics Holdings (SONN)
- rega saham lan target rega konsensus:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Sonnet BioTherapeutics|SONN - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Sonnet BioTherapeutics|SONN - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Sonnet BioTherapeutics Holdings Inc.|SONN - Utang jangka dawa|Utang jangka cendhak perusahaan Sonnet BioTherapeutics|Rasio cepet sonnetbio.com
- data bathi bisnis lan rasio investasi:
SONN - Bathi resik|Bathi sing dikarepake Sonnet BioTherapeutics|SONN - Kapitalisasi marang bathi resik|Prakiraan rega marang bathi Sonnet BioTherapeutics Holdings|SONN - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Sonnet BioTherapeutics|SONN - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Sonnet BioTherapeutics|SONN - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan sonnetbio.com|SONN - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Sonnet BioTherapeutics
- rincian pendapatan lan dodolan:
Ringkesan analisis perusahaan:Sonnet BioTherapeutics Holdings Inc. SONN
Sonnet BioTherapeutics is advancing immuno-oncology while strictly adhering to bioethical standards and environmental safety principles regarding waste disposal. The ratio of current market value to projected annual revenue via the expected P/S metric allows for an assessment of capitalization fairness relative to future earnings, neutralizing time gaps between reports and alerting investors to the risk of overpayment during sharp price spikes.
Analisis pesaing
ImmunityBio Inc - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Corp IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (arcusbio.com) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Biopharmaceuticals (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Tango Pharma (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune)|Rega forward marang dodolan LYEL|innate-pharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pyxis Oncology|Compugen Limited (CGEN) - Rasio rega marang prakiraan pendapatan|IO Biotech, Inc. - Rega forward marang dodolan|STRO (sutrobio.com) - Multiplikator Forward P/S|Multiplikator Forward P/S MiNK Therapeutics Inc.|Rasio rega marang prakiraan pendapatan werewolftx.com (HOWL)|IMMX: Rega mangsa ngarep marang pendapatan|alxoncology.com - Multiplikator forward rega marang pendapatan|CUE - Multiplikator forward rega marang pendapatan|PDSB - Rasio rega marang prakiraan pendapatan|MAIA Biotechnology, Inc. (MAIA) - Multiplikator forward rega marang pendapatan|LIMN: Multiplikator Forward P/S|LAVA Therapeutics N.V. (LVTX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan NXTC|Multiplikator Forward P/S leaptx.com|Multiplikator Forward P/S INTS|Rasio kapitalisasi marang dodolan sing dikarepake Sensei Biotherapeutics, Inc.|Multiplikator Forward P/S TOVX (Theriva Corp)|Rasio kapitalisasi marang dodolan sing dikarepake gritstonebio.com (GRTS)|kinetabio.com - Multiplikator Forward P/S|NexImmune (NEXI) - Multiplikator forward rega marang pendapatan|turnstonebio.com (TSBX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vaccinex, Inc (VCNX)|Multiplikator forward rega marang pendapatan HARP
